FIGS Stock: Can It Climb to $20? Assessing the +110% Upside Case

Key Takeaways

• Price Target: $20 per share — a level not yet reached in FIGS's current cycle and representing roughly 110% upside from recent prices around $9.50.
• Strongest Bullish Factors: Accelerating revenue growth (28% in Q1 2026), international expansion gaining traction, active customers surpassing 3 million, and a debt-free balance sheet with $277 million in net cash.
• Biggest Risks: Tariff pressures on sourcing costs, freight headwinds, margin recovery still in progress, and the stock's elevated valuation even after the recent pullback.
• Key Technical Levels: The $8–$10 zone serves as a critical support area; a sustained move above the 200-day moving average near $12.79 would signal recovering momentum toward prior resistance near $15–$17.
• Bottom Line: Reaching $20 is plausible over a multi-year horizon if international expansion and margin recovery accelerate, but the near-term path is challenged by tariff uncertainty and the stock's recent loss of momentum.

Why Investors Are Watching the $20 Level

FIGS, Inc., the direct-to-consumer healthcare apparel company, has experienced a dramatic round-trip over the past year. After trading below $4 in early 2025, the stock staged a powerful recovery, surging above $17 by March 2026 behind strong earnings and a flurry of analyst upgrades. Since that peak, however, shares have retreated sharply, settling near $9.50 as of late July 2026. The question now confronting investors is whether the growth story can regain enough momentum to push the stock toward $20 — a psychologically significant level that would represent new highs for this cycle and align with the most bullish Wall Street targets.

Company Overview

Founded in 2013 by Heather Hasson and Trina Spear, FIGS disrupted the staid medical uniform industry by designing premium scrubs and healthcare apparel with the fit, feel, and branding sensibility of athleisure. The company went public in May 2021 at $22 per share and briefly traded above $50 during the pandemic-era surge in healthcare spending. Today, FIGS generates trailing twelve-month revenue of approximately $666 million, serves over 3 million active customers, and operates across North America, Europe, Asia Pacific, and the Middle East through its e-commerce platform and a growing network of physical retail locations.

What Could Drive the Next Leg Higher

Several catalysts could support a move toward $20. First, international expansion is delivering tangible results — international sales grew approximately 50% year-over-year in the most recent quarter. The company's TEAMS platform, which serves healthcare institutions through bulk purchasing, represents a largely untapped B2B opportunity. Management raised full-year 2026 revenue growth guidance to 14%–16% following Q1 results that delivered $159.9 million in revenue, a 28% increase from the prior year. The company's balance sheet remains a source of strength, with $277 million in net cash and no long-term debt, providing ample flexibility for share buybacks and strategic investments. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Wall Street has taken notice. Oppenheimer carries a $22 price target with an Outperform rating, while BTIG maintains a Buy rating with a $20 target. KeyBanc's Overweight rating and $19 target reflect confidence that the company's "growth algorithm remains intact," citing healthy customer engagement trends and limited resistance to recent pricing actions.

What Could Prevent the Move

Tariffs remain the most significant obstacle. Section 122 tariffs, currently at 10% and potentially rising to 15%, directly pressure gross margins on imported goods. Management acknowledged that freight cost headwinds and the pause of a duty drawback program will create an uneven margin cadence throughout 2026. While Q1 gross margin improved modestly to 67.7%, the full-year outlook assumes only slight improvement over 2025's 66.5%.

Competition also deserves attention. The healthcare apparel market, while historically fragmented, is attracting attention from larger players. Lower-priced alternatives continue to test FIGS's premium positioning, and the company must demonstrate that its brand strength can sustain pricing power without relying on promotions that erode profitability.

Technical Levels That Matter

The stock's technical picture presents a mixed outlook. After peaking at $17.48 in early March 2026, shares have fallen below both the 50-day moving average near $12.69 and the 200-day moving average near $12.79 — a configuration that typically signals bearish momentum. The $9–$10 zone represents an important support area; a breakdown below this range could expose the stock to the mid-$7 area, where Goldman Sachs's prior price target sat before its February upgrade. On the upside, reclaiming the $12–$13 region would be a necessary first step toward rebuilding confidence, with the prior peak near $17 serving as the next major resistance zone before $20 becomes a realistic discussion. From what I see, monitoring these levels closely helps frame the risk-reward picture.

Analyst Opinions and Price Targets

The analyst community holds a Moderate Buy consensus on FIGS, with an average 12-month price target near $15.93, according to MarketBeat data from 11 covering analysts. However, targets span a wide range — from a bearish $7.50 to a bullish $22.00 — reflecting genuine disagreement about the company's trajectory. The clustering of targets between $15 and $20 suggests that even bullish analysts are tempering enthusiasm with caution around margin recovery and valuation. Notably, the average target represents approximately 56% upside from current levels but still falls meaningfully short of $20, underscoring that the $20 objective requires execution beyond the consensus base case.

Valuation Perspective

Even after its recent decline, FIGS trades at a trailing P/E ratio above 40 — a premium multiple that leaves little room for disappointment. The forward P/E near 34 suggests the market expects significant earnings growth to materialize. For the stock to reach $20 without multiple expansion, EPS would need to roughly double from current levels. With FY2026 consensus EPS estimates around $0.25–$0.27 and FY2027 projections near $0.35, reaching $20 would likely require maintaining an elevated growth multiple while delivering consistent earnings beats — a demanding but not impossible combination.

Final Assessment

The path to $20 for FIGS stock is plausible but conditional. The company's revenue growth trajectory, international momentum, fortress balance sheet, and growing customer base provide a credible foundation. However, the near-term reality includes tariff headwinds, margin uncertainty, and a stock that has lost technical momentum. Reaching $20 would likely require multiple catalysts to align: successful mitigation of tariff impacts, sustained margin expansion, accelerating international contribution, and a broader market environment supportive of growth-at-a-reasonable-price narratives. Investors should monitor the upcoming Q2 earnings report in early August 2026 for updated guidance on margins, tariff assumptions, and progress on international initiatives — these will be critical signposts on the road to $20.

Using Tickeron’s AI Daily Buy/Sell Signals in My Process

Navigating a stock with as much volatility as FIGS requires timely, data-driven insight. In my own analysis, I often rely on Tickeron’s AI Daily Buy/Sell Signals to monitor shifting conditions across thousands of stocks and ETFs. The platform’s AI evaluates technical patterns and fundamentals to generate Buy, Sell, or Hold signals, helping me stay ahead of potential trend changes without replacing my own due diligence.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Sergey Savastiouk|Expert

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.

Notable companies

Industry description

Market Cap

High and low price notable news

Volume